Targeting Proteins to Antigen-Presenting Cells and Induction of Cytokines as a Basis for Adjuvant Activity
The need for improved and new vaccines is evident. While live virus vaccines have been very useful, they can produce severed infections in persons whose immune systems are compromised because of congenital deficiency, malnutrition or infections (notably HIV). If subunit antigens can elicit equivalent protection they are preferred. Preparation of antigens by recombinant technology has opened up the possibility of a new generation of vaccines, but a safe and efficacious adjuvant is a necessary component. The only adjuvant approved for human use is aluminum hydroxide or phosphate. While alum is an effective adjuvant for bacterial toxoids it has limited efficacy in other situations, for reasons that will be discussed below.
KeywordsCholesterol Surfactant Arthritis Lymphoma Interferon
Unable to display preview. Download preview PDF.
- Arden, N. H., Patriarca, P. A., and Kendal, A. P., 1986, Experiences in the use and efficacy of influenza vaccine in nursing homes, in: “Options for Control of Influenza”, A. P. Kendal, and P. A. Patriarca, eds., Alan R. Liss, New York.Google Scholar
- Bomford, R., 1989, Aluminium salts: perspectives in their use as adjuvants, in: “Immunological Adjuvants and Vaccines”, G. Gregoriadis, A. C. Allison and G. Poste, eds., Plenum Press, London.Google Scholar
- Braemer, A., Peterson, M., Renneke, G., Bass, E., Allison, A. C, Byars, N. E., and Fraser, D., 1984, Effect of inactivated FeLV vaccines on the development of persistent viremia, Proc. 65th Conf. Res. Workers in Animal diseases (E.M. Kohler) (p. 10).Google Scholar
- Fraser-Smith, E. B., Waters, R. V. and Matthews, T. R., 1982, Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice, Infect. Immun., 35:105.PubMedGoogle Scholar
- Gosselin, R. E., Hodge, H. C., Smith, R. P. and Gleason, M. N., 1976, “Clinical toxicology of commercial products,” Fourth Edition, Williams & Wilkins Company, Baltimore.Google Scholar
- Marx, P. A., Pedersen, N. C, Lerche, N. W., Osborn, K. G., Lowenstine, L. J., Lackner, A. A., Maul, D. H., Kwang, H.-S., Kluge, J. D., Zaiss, C. P., Sharpe, V., Spinner, A. P., Allison, A. C. and Gardner, M. B., 1986, Prevention of simian acquired immunodeficiency syndrome with a formalin-inactivated Type D retrovirus vaccine, J. Virol., 60:431.PubMedGoogle Scholar
- Murphey-Corb, M., Martin, L. N., Davison-Fairburn, B., Okawa, S., Baskin, G. B., Zhang, J.-Y., Mbntelaro, R. C, Miller, M., West, M., Allison, A. C. and Eppstein, D. A., 1989, A formalin inactivated whole simian immunodeficiency virus vaccine confers protection in macaques, Science, 246:1293.PubMedCrossRefGoogle Scholar
- Nicholson, K. G., Tyrrell, D. A. J., Harrison, P., Potter, C. W., Jennings, R., Clark, A., Schild, G. C, Wood, J. M., Yells, R., Seagrott, V., Huggens, A. and Anderson, S. G., 1979, Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological and clinical reactions, J. Biol. Stand., 7:123.PubMedCrossRefGoogle Scholar
- Ribi, E., Ulrich, J. T. and Masihi, K. N., 1987, Immunopotentiating activities of monophosphoryl lipid A, in: “Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Nonspecific Resistance,” J. A. Majde, ed., Alan R. Liss, New York.Google Scholar